PROK - ProKidney Corp.

Momentum: Bearish

Recent News

ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference - ProKidney ( NASDAQ:PROK )

Benzinga • 2 weeks, 5 days ago • score: 0.32

WINSTON-SALEM, N.C., Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- ProKidney Corp. PROK ( "ProKidney" or the "Company" ) , a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease ( CKD ) , today announced that senior members of the management team will be participating ...

Bullish

ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference

GlobeNewswire • 2 weeks, 5 days ago • score: 0.35

WINSTON-SALEM, N.C., Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- ProKidney Corp. ( Nasdaq: PROK ) ( "ProKidney" or the "Company" ) , a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease ( CKD ) , today announced that senior members of the management team will be ...

Bullish

Meet the Biotech Stock That Rocketed 775% Higher

Motley Fool • 1 month, 3 weeks ago • score: 0.20

If you're looking for stocks that can make dramatic movements in a short time frame, the biotechnology space has what you crave. At the end of June, ProKidney ( NASDAQ: PROK ) stock was languishing at less than $1 per share. When the market closed on July 10, the stock was trading at $5.18 per ...

Bullish

PROKIDNEY CP ( PROK ) Upgraded to Strong Buy: What Does It Mean for the Stock?

Zacks Commentary • 1 month, 4 weeks ago • score: 0.35

PROKIDNEY CP (PROK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Neutral

Best Momentum Stocks to Buy for July 17th

Zacks Commentary • 1 month, 4 weeks ago

PROK, ROKU and PHAR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 17, 2025.

Bullish

This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy?

Motley Fool • 1 month, 4 weeks ago • score: 0.30

Biotech stocks can be risky but exciting investments because they can soar quickly on positive news, such as a drug approval or simply the hope that they may soon have an approved treatment. They can drop just as quickly on negative news.

Neutral

New Strong Buy Stocks for July 17th

Zacks Commentary • 1 month, 4 weeks ago

PHAR, ROKU, PROK, MAG and KRP have been added to the Zacks Rank #1 (Strong Buy) List on July 17, 2025.

Bullish

ProKidney Corp. ( PROK ) is a Great Momentum Stock: Should You Buy?

Zacks Commentary • 1 month, 4 weeks ago • score: 0.46

Does ProKidney Corp. (PROK) have what it takes to be a top stock pick for momentum investors? Let's find out.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

ProKidney Corporation. The company is headquartered in Winston-Salem, North Carolina.

52W High

$5.95

52W Low

$0.46

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.79

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

2.13

EV/Revenue (<3 favorable)

25.48

P/S (TTM) (<3 favorable)

3438.00

P/B (<3 favorable)

97.15

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

28.84%

Institutions (25–75% balanced)

30.46%

Shares Outstanding

134,994,000

Float

86,723,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

527,000

Gross Profit (TTM)

527,000

EPS (TTM)

-0.56

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-179.68%

ROE (TTM) (>15% strong)

-0.41%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.0179

-0.0284

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025